Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades
Overview
Authors
Affiliations
Background And Aims: While the incidence rates of hepatocellular carcinoma (HCC) are increasing, there are limited comprehensive data on demographic-specific incidence and mortality trends in the USA. We aimed to evaluate recent trends in HCC incidence and mortality among different demographic groups in the USA.
Methods: Age-adjusted HCC incidence rates were calculated from the Centers for Disease Control's United States Cancer Statistics database, which combines incidence data on newly diagnosed cancer cases and covers approximately 98% of the population in the USA. Additionally, age-adjusted HCC mortality rates were obtained from the Centers for Disease Control's National Center for Health Statistics database, which offers comprehensive coverage spanning nearly 100% of deaths attributed to HCC in the USA. Rates were stratified by sex, age (older [≥55 years] and younger [<55 years] adults), race and ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Non-Hispanic Asian/Pacific Islander, and Non-Hispanic American Indian/Alaska Native), and tumor stage at diagnosis (early and late). Annual and average annual percentage change (AAPC) were calculated using joinpoint regression. A sex-specific pairwise comparison was conducted.
Results: Between 2001 and 2020, there were 467,346 patients diagnosed with HCC (26.0% women), with increasing incidence in both sexes without significant difference (=0.65). In younger adults (78,169 patients), the incidence decreased in men but not in women (AAPC difference=-2.39, =0.002). This was seen in various racial and ethnic groups, mostly driven by early-stage tumors (AAPC difference=-2.65, =0.02). There were 329,973 deaths attributed to HCC between 2000 and 2020 (28.4% women). In younger adults (43,093 deaths), mortality decreased in men at a greater rate than in women (AAPC difference=1.61, =0.007). This was seen in various racial and ethnic groups, most notably in non-Hispanic American Indian/Alaska Natives (AAPC difference=-4.51, =0.01).
Conclusions: Nationwide USA data, covering nearly all HCC cases, show an increasing incidence and mortality over the last two decades. In younger adults, there was a decreasing incidence in men but not in women, due to early-stage tumors. Mortality improved in younger men at a greater rate than in women, especially in Non-Hispanic American Indian/Alaska Natives. Future studies are warranted to identify the risk factors associated with the occurrence and outcomes of HCC in demographic-specific populations, especially younger women.
Almazan E, Chung R Gastro Hep Adv. 2025; 4(1):100535.
PMID: 39758847 PMC: 11699276. DOI: 10.1016/j.gastha.2024.08.014.
Abboud Y, Malhotra R, Maan M, Mathew A, Abboud I, Pan C World J Methodol. 2024; 14(4):95598.
PMID: 39712566 PMC: 11287541. DOI: 10.5662/wjm.v14.i4.95598.
Xiong X, Guo J Pharmacoeconomics. 2024; 43(3):271-282.
PMID: 39546248 DOI: 10.1007/s40273-024-01453-0.
Health disparities in cirrhosis care and liver transplantation.
Goldberg D, Wilder J, Terrault N Nat Rev Gastroenterol Hepatol. 2024; 22(2):98-111.
PMID: 39482363 DOI: 10.1038/s41575-024-01003-1.
Complex Multi-site Stereotactic Body Re-irradiation With CT-Guided Online Adaptive Radiotherapy.
Sievert D, DSouza A, Zhao X, Prusator M, Mazur T, Kim H Cureus. 2024; 16(9):e68559.
PMID: 39364455 PMC: 11449465. DOI: 10.7759/cureus.68559.